Document is current

Article History

Received: 1 April 2025

Accepted: 28 July 2025

First Online: 3 September 2025

Declarations

:

: JT reports personal financial interest in form of scientific consultancy role for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, Lilly, Menarini, Merus, MSD, Novartis, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, Quantro Therapeutics, Scandion Oncology, Scorpion Therapeutics, Servier, Sotio Biotech, Taiho, Takeda Oncology and Tolremo Therapeutics, and stocks from Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP. RS reports personal financial interest in form of Consultant or Advisory Role (including Steering Committees, DSMBs): Laboratorios Esteve, Sanofi Genzyme; and speaking/teaching activities: Sanofi-Aventis, GlaxoSmithKline and WNT Pharma. Co-owner of SACE Medhealth, commercial medical education company, until April 2022; subsequently owned by spouse until December 2023. DC has received honoraria from AstraZeneca, Novartis, Incyte, Sophia genetics and Thermofisher for speaking/teaching at educational activities: Sanofi-Aventis, GlaxoSmithKline. AP reports grants from AstraZeneca, Novartis, Daiichi Sankyo, Pfizer, Reveal Genomics, and WNTRoche and personal fees from Roche, AstraZeneca, Novartis, Daiichi Sankyo, Pfizer, Ona Therapeutics, Peptomyc, Reveal Genomics; in addition, AP reports patents for HER2DX, and DNADX issued and licensed to Reveal Genomics. LM is past member of data monitoring committees for clinical trials sponsored by Novartis, Shionogi and Incyte; had a consulting role for Novartis, Norgine, Boehringer, Ymabs, Merck, Roche, Bayer and Shionogi; participated in educational activities organized by Bayer and Eusa Pharma and received travel expenses from Eusa Pharma; is President of SIOPEN (European neuroblastoma research cooperative group), an organization which receives royalties for the sales of dinutuximab beta. J-M.R., reports consulting/advisory roles at Incyte, Pfizer, Bristol Myers Squibb, Novartis, and Takeda; and research funding from Amgen. JA has received consulting, advisory or speaker fees from Roche, Pfizer, MSD, Gilead, Menarini, Lilly, Novartis and AstraZeneca Daiichi-Sankyo; research funding or grant support trials by Roche, Pfizer, Amgen, Novartis, MSD, Lilly, AstraZeneca Daiichi-Sankyo; and travel and accommodation support from Gilead and AstraZeneca Daiichi-Sankyo. Holds a patent on LCOR, EGFR ECD (licensed) and stock options in Inbiomotion. BB received honoraria for speaker, consultancy or advisory role from Astra-Zeneca, Janssen, Merck-Serono, Novartis, Roche, Thermo Fisher, Pfizer, BMS, and research grants from Astra-Zeneca, Thermo Fisher, Roche Diagnostics, Roche Farma. X. M.-G.; Lectures and associated travel expenses: Roche Farma, Qiagen, Ferrer Internacional, Novartis, Menarini, Biocartis, Agilent-Dako, Leyca, Reig Jofre, Sysmex, MSD, Astra-Zeneca, BMS, GSK, Clovis. Eisai; Advisory Boards: Astra-Zeneca, Lilly, Amgen, GSK, Janssen, Illumina, MiMark Diagnostics, MSD, Daiichi Sankyo, Inc, Abbvie. FB reports financial interest in form of consultancy role and speaking/teaching activities for Johnson & Johnson, Abbvie, Novartis, F. Hoffmann-La Roche Ltd, Genentech Inc, Lilly, Beigene, Ascentage, AstraZeneca, Boehringer Ingelheim, MSD, Allogene, Takeda, Kite, Gilead. JMB received honoraria for speaker from Roche, Abbvie, and MSD.

: The program is part of the standard of care in Catalonia’s public healthcare system. The current study adheres to ethical standards established by the Bioethics Committee of Catalonia and complies with the principles of the Declaration of Helsinki.